IRAY TECHNOLOGY(SH:688301) ZHESHANG SECURITIES·2025-05-20 08:42Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company experienced a revenue of 1.83 billion yuan in 2024, a year-over-year decrease of 1.7%, and a net profit attributable to shareholders of 470 million yuan, down 23.4% year-over-year. In Q1 2025, the revenue was 480 million yuan, a decrease of 1.9% year-over-year, while the net profit attributable to shareholders was 140 million yuan, an increase of 2.7% year-over-year [1][2] - The company is currently in a strategic upgrade phase, with ongoing construction projects and product line expansions. Although short-term pressures from fixed asset depreciation may affect profits, the long-term outlook remains positive due to the rapid growth in the sectors the company operates in [2][4] - New product launches, such as the 64-row medical CT detector module and high-end DSA detectors, have entered mass production. The company has also made significant progress in developing key technologies related to photon counting detectors [2][3] Performance Analysis - In 2024, the company's gross margin was 50.1%, a decrease of 7.7 percentage points year-over-year, and the net profit margin was 24.6%, down 7.9 percentage points year-over-year. The changes in product mix are believed to be the main reason for this decline [9] - The operating cash flow for 2024 was 360 million yuan, a year-over-year increase of 5.9%, with the net cash flow from operating activities accounting for 94.2% of net operating income, showing a significant improvement [9] Financial Forecast and Valuation - The company is expected to achieve earnings per share (EPS) of 4.18 yuan, 5.19 yuan, and 6.30 yuan for the years 2025, 2026, and 2027, respectively. The current stock price corresponds to a price-to-earnings (P/E) ratio of 29.7 times for 2025. Given the company's successful expansion of new products and pipelines, the long-term growth potential is considered substantial [10][12]